CDC6 may serve as an indicator of lung adenocarcinoma prognosis and progression based on TCGA and GEO data mining and experimental analyses

Lou,Hao; Wu,Zelai; Wei,Guangyou

doi:10.3892/or.2024.8694

CDC6 may serve as an indicator of lung adenocarcinoma prognosis and progression based on TCGA and GEO data mining and experimental analyses

Authors:
- Hao Lou
- Zelai Wu
- Guangyou Wei
View Affiliations

Affiliations: School of Medicine, Anhui University of Science and Technology, Huainan, Anhui 232001, P.R. China, Department of Surgery, Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, Zhejiang 310058, P.R. China
Published online on: January 3, 2024 https://doi.org/10.3892/or.2024.8694
Article Number: 35
Copyright: © Lou et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Lung adenocarcinoma (LUAD) is one of the most lethal types of cancer worldwide, and accurately predicting patient prognosis is an important challenge. Gene prediction models, which are known for their simplicity and efficiency, have the potential to be used for prognostic predictions. However, the availability of models with true clinical value is limited. The present study integrated tissue sequencing and the clinical information of patients with LUAD from The Cancer Genome Atlas and Gene Expression Omnibus databases using bioinformatics. This comprehensive approach enabled the identification of 252 differentially expressed genes. Subsequently, univariate and multivariate Cox analyses were performed using these genes, and 14 and 3 genes [including cell division cycle 6 (CDC6), hyaluronan mediated motility receptor and STIL centriolar assembly protein] were selected for the construction of two prognostic models. Notably, the 3‑gene prognostic model exhibited a comparable predictive ability to that of the 14‑gene model. Functionally, pathway enrichment analysis revealed that CDC6 played a role in regulating the cell cycle and promoting tumor staging. To further investigate the relevance of CDC6, in vitro experiments involving the downregulation of CDC6 expression were conducted, which resulted in significant inhibition of tumor cell migration, invasion and proliferation. Moreover, in vivo experiments demonstrated that downregulating CDC6 expression significantly reduced the burden and metastasis of in situ lung tumors in mice. These findings suggested that CDC6 may be a critical gene involved in the development and prognosis of LUAD. In summary, the present study successfully constructed a simple yet accurate prognostic prediction model consisting of 3 genes. Additionally, the functional importance of CDC6 as a key gene in the model was identified. These findings lay a crucial foundation for further exploration of prognostic prediction models and a deeper understanding of the functional mechanisms of CDC6. Notably, these results have potential clinical implications for improving personalized treatment and prognosis evaluation for patients with LUAD.

View Figures

View References

1	Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A and Bray F: Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 71:209–249. 2021. View Article : Google Scholar : PubMed/NCBI
2	Lawrence MS, Stojanov P, Polak P, Kryukov GV, Cibulskis K, Sivachenko A, Carter SL, Stewart C, Mermel CH, Roberts SA, et al: Mutational heterogeneity in cancer and the search for new cancer-associated genes. Nature. 499:214–218. 2013. View Article : Google Scholar : PubMed/NCBI
3	Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA and Jemal A: Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 68:394–424. 2018. View Article : Google Scholar : PubMed/NCBI
4	Park CK, Cho HJ, Choi YD, Oh IJ and Kim YC: A phase II trial of osimertinib in the second-line treatment of non-small cell lung cancer with the EGFR T790M mutation, detected from circulating tumor DNA: LiquidLung-O-Cohort 2. Cancer Res Treat. 51:777–787. 2019. View Article : Google Scholar : PubMed/NCBI
5	Chen S, Ren Y and Duan P: Biomimetic nanoparticle loading obatoclax mesylate for the treatment of non-small-cell lung cancer (NSCLC) through suppressing Bcl-2 signaling. Biomed Pharmacother. 129:1103712020. View Article : Google Scholar : PubMed/NCBI
6	Zhou J, Hui X, Mao Y and Fan L: Identification of novel genes associated with a poor prognosis in pancreatic ductal adenocarcinoma via a bioinformatics analysis. Biosci Rep. 39:BSR201906252019. View Article : Google Scholar : PubMed/NCBI
7	Bakht MK, Lovnicki JM, Tubman J, Stringer KF, Chiaramonte J, Reynolds MR, Derecichei I, Ferraiuolo RM, Fifield BA, Lubanska D, et al: Differential expression of glucose transporters and hexokinases in prostate cancer with a neuroendocrine gene signature: A mechanistic perspective for ¹⁸F-FDG imaging of PSMA-suppressed tumors. J Nucl Med. 61:904–910. 2020. View Article : Google Scholar : PubMed/NCBI
8	Kim S, Shin W, Lee YM, Mun S and Han K: Differential expressions of L1-chimeric transcripts in normal and matched-cancer tissues. Anal Biochem. 600:1137692020. View Article : Google Scholar : PubMed/NCBI
9	Zhang J, Guo X, Hamada T, Yokoyama S, Nakamura Y, Zheng J, Kurose N, Ishigaki Y, Uramoto H, Tanimoto A and Yamada S: Protective effects of peroxiredoxin 4 (PRDX4) on cholestatic liver injury. Int J Mol Sci. 19:25092018. View Article : Google Scholar : PubMed/NCBI
10	Jiang J, Liu HL, Tao L, Lin XY, Yang YD, Tan SW and Wu B: Let-7d inhibits colorectal cancer cell proliferation through the CST1/p65 pathway. Int J Oncol. 53:781–790. 2018.PubMed/NCBI
11	Du SM: The SNHG16/miR-30a axis promotes breast cancer cell proliferation and invasion by regulating RRM2. Neoplasma. 67:567–575. 2020. View Article : Google Scholar : PubMed/NCBI
12	Zhuang S, Li L, Zang Y, Li G and Wang F: RRM2 elicits the metastatic potential of breast cancer cells by regulating cell invasion, migration and VEGF expression via the PI3K/AKT signaling. Oncol Lett. 19:3349–3355. 2020.PubMed/NCBI
13	Xia P, Zhang H, Xu K, Jiang X, Gao M, Wang G, Liu Y, Yao Y, Chen X, Ma W, et al: MYC-targeted WDR4 promotes proliferation, metastasis, and sorafenib resistance by inducing CCNB1 translation in hepatocellular carcinoma. Cell Death Dis. 12:6912021. View Article : Google Scholar : PubMed/NCBI
14	Zhang H, Zhang X, Li X, Meng WB, Bai ZT, Rui SZ, Wang ZF, Zhou WC and Jin XD: Effect of CCNB1 silencing on cell cycle, senescence, and apoptosis through the p53 signaling pathway in pancreatic cancer. J Cell Physiol. 234:619–631. 2018. View Article : Google Scholar : PubMed/NCBI
15	Okayama H, Kohno T, Ishii Y, Shimada Y, Shiraishi K, Iwakawa R, Furuta K, Tsuta K, Shibata T, Yamamoto S, et al: Identification of genes upregulated in ALK-positive and EGFR/KRAS/ALK-negative lung adenocarcinomas. Cancer Res. 72:100–111. 2012. View Article : Google Scholar : PubMed/NCBI
16	Xu L, Lu C, Huang Y, Zhou J, Wang X, Liu C, Chen J and Le H: SPINK1 promotes cell growth and metastasis of lung adenocarcinoma and acts as a novel prognostic biomarker. BMB Rep. 51:648–653. 2018. View Article : Google Scholar : PubMed/NCBI
17	Schabath MB, Welsh EA, Fulp WJ, Chen L, Teer JK, Thompson ZJ, Engel BE, Xie M, Berglund AE, Creelan BC, et al: Differential association of STK11 and TP53 with KRAS mutation-associated gene expression, proliferation and immune surveillance in lung adenocarcinoma. Oncogene. 35:3209–3216. 2016. View Article : Google Scholar : PubMed/NCBI
18	Rousseaux S, Debernardi A, Jacquiau B, Vitte AL, Vesin A, Nagy-Mignotte H, Moro-Sibilot D, Brichon PY, Lantuejoul S, Hainaut P, et al: Ectopic activation of germline and placental genes identifies aggressive metastasis-prone lung cancers. Sci Transl Med. 5:186ra662013. View Article : Google Scholar : PubMed/NCBI
19	Director's Challenge Consortium for the Molecular Classification of Lung Adenocarcinoma, . Shedden K, Taylor JM, Enkemann SA, Tsao MS, Yeatman TJ, Gerald WL, Eschrich S, Jurisica I, Giordano TJ, et al: Gene expression-based survival prediction in lung adenocarcinoma: A multi-site, blinded validation study. Nat Med. 14:822–827. 2008. View Article : Google Scholar : PubMed/NCBI
20	Tungsukruthai S, Sritularak B and Chanvorachote P: Cycloartobiloxanthone inhibits migration and invasion of lung cancer cells. Anticancer Res. 37:6311–6319. 2017.PubMed/NCBI
21	Stoellinger HM and Alexanian AR: Modifications to the transwell migration/invasion assay method that eases assay performance and improves the accuracy. Assay Drug Dev Technol. 20:75–82. 2022. View Article : Google Scholar : PubMed/NCBI
22	Xu L, Wang X, Wang W, Sun M, Choi WJ, Kim JY, Hao C, Li S, Qu A, Lu M, et al: Enantiomer-dependent immunological response to chiral nanoparticles. Nature. 601:366–373. 2022. View Article : Google Scholar : PubMed/NCBI
23	Cheng Y, Shen Z, Gao Y, Chen F, Xu H, Mo Q, Chu X, Peng CL, McKenzie TT, Palacios BE, et al: Phase transition and remodeling complex assembly are important for SS18-SSX oncogenic activity in synovial sarcomas. Nat Commun. 13:27242022. View Article : Google Scholar : PubMed/NCBI
24	Li HJ, Ke FY, Lin CC, Lu MY, Kuo YH, Wang YP, Liang KH, Lin SC, Chang YH, Chen HY, et al: ENO1 promotes lung cancer metastasis via HGFR and WNT signaling-driven epithelial-to-mesenchymal transition. Cancer Res. 81:4094–4109. 2021. View Article : Google Scholar : PubMed/NCBI
25	Li H, Han D, Hou Y, Chen H and Chen Z: Statistical inference methods for two crossing survival curves: A comparison of methods. PLoS One. 10:e01167742015. View Article : Google Scholar : PubMed/NCBI
26	Kim GS, Kang J, Bang SW and Hwang DS: Cdc6 localizes to S- and G2-phase centrosomes in a cell cycle-dependent manner. Biochem Biophys Res Commun. 456:763–767. 2015. View Article : Google Scholar : PubMed/NCBI
27	Li Z, Qi F and Li F: Establishment of a gene signature to predict prognosis for patients with lung adenocarcinoma. Int J Mol Sci. 21:84792020. View Article : Google Scholar : PubMed/NCBI
28	Qin J, Xu Z, Deng K, Qin F, Wei J, Yuan L, Sun Y, Zheng T and Li S: Development of a gene signature associated with iron metabolism in lung adenocarcinoma. Bioengineered. 12:4556–4568. 2021. View Article : Google Scholar : PubMed/NCBI
29	Siegel RL, Miller KD and Jemal A: Cancer statistics, 2020. CA Cancer J Clin. 70:7–30. 2020. View Article : Google Scholar : PubMed/NCBI
30	Behera M, Owonikoko TK, Gal AA, Steuer CE, Kim S, Pillai RN, Khuri FR, Ramalingam SS and Sica GL: Lung adenocarcinoma staging using the 2011 IASLC/ATS/ERS classification: A pooled analysis of adenocarcinoma in situ and minimally invasive adenocarcinoma. Clin Lung Cancer. 17:e57–e64. 2016. View Article : Google Scholar : PubMed/NCBI
31	Ye S, Liu Y, Fuller AM, Katti R, Ciotti GE, Chor S, Alam MZ, Devalaraja S, Lorent K, Weber K, et al: TGFβ and hippo pathways cooperate to enhance sarcomagenesis and metastasis through the hyaluronan-mediated motility receptor (HMMR). Mol Cancer Res. 18:560–573. 2020. View Article : Google Scholar : PubMed/NCBI
32	Yang D, Ma Y, Zhao P, Ma J and He C: Systematic screening of protein-coding gene expression identified HMMR as a potential independent indicator of unfavorable survival in patients with papillary muscle-invasive bladder cancer. Biomed Pharmacother. 120:1094332019. View Article : Google Scholar : PubMed/NCBI
33	Man Y, Cao J, Jin S, Xu G, Pan B, Shang L, Che D, Yu Q and Yu Y: Newly identified biomarkers for detecting circulating tumor cells in lung adenocarcinoma. Tohoku J Exp Med. 234:29–40. 2014. View Article : Google Scholar : PubMed/NCBI
34	Li W, Pan T, Jiang W and Zhao H: HCG18/miR-34a-5p/HMMR axis accelerates the progression of lung adenocarcinoma. Biomed Pharmacother. 129:1102172020. View Article : Google Scholar : PubMed/NCBI
35	Wang X, Xia S, Li H, Wang X, Li C, Chao Y, Zhang L and Han C: The deubiquitinase USP10 regulates KLF4 stability and suppresses lung tumorigenesis. Cell Death Differ. 27:1747–1764. 2020. View Article : Google Scholar : PubMed/NCBI
36	Roberts MS, Anstine LJ, Finke VS, Bryson BL, Webb BM, Weber-Bonk KL, Seachrist DD, Majmudar PR and Keri RA: KLF4 defines the efficacy of the epidermal growth factor receptor inhibitor, erlotinib, in triple-negative breast cancer cells by repressing the EGFR gene. Breast Cancer Res. 22:662020. View Article : Google Scholar : PubMed/NCBI
37	Kawabata KC, Ehata S, Komuro A, Takeuchi K and Miyazono K: TGF-β-induced apoptosis of B-cell lymphoma ramos cells through reduction of MS4A1/CD20. Oncogene. 32:2096–2106. 2013. View Article : Google Scholar : PubMed/NCBI
38	Kubota T, Sasaki Y, Shiozawa E, Takimoto M, Hishima T and Chong JM: Age and CD20 expression are significant prognostic factors in human herpes virus-8-negative effusion-based lymphoma. Am J Surg Pathol. 42:1607–1616. 2018. View Article : Google Scholar : PubMed/NCBI
39	Ito H, Tsunoda T, Riku M, Inaguma S, Inoko A, Murakami H, Ikeda H, Matsuda M and Kasai K: Indispensable role of STIL in the regulation of cancer cell motility through the lamellipodial accumulation of ARHGEF7-PAK1 complex. Oncogene. 39:1931–1943. 2020. View Article : Google Scholar : PubMed/NCBI
40	Wang J, Zhang Y, Dou Z, Jiang H, Wang Y, Gao X and Xin X: Knockdown of STIL suppresses the progression of gastric cancer by down-regulating the IGF-1/PI3K/AKT pathway. J Cell Mol Med. 23:5566–5575. 2019. View Article : Google Scholar : PubMed/NCBI
41	Patwardhan D, Mani S, Passemard S, Gressens P and El Ghouzzi V: STIL balancing primary microcephaly and cancer. Cell Death Dis. 9:652018. View Article : Google Scholar : PubMed/NCBI
42	von Ehr A, Attaai A, Neidert N, Potru PS, Ruß T, Zöller T and Spittau B: Inhibition of microglial TGFβ signaling increases expression of Mrc1. Front Cell Neurosci. 14:662020. View Article : Google Scholar : PubMed/NCBI
43	Liu Q, Bai W, Huang F, Tang J and Lin X: Downregulation of microRNA-196a inhibits stem cell self-renewal ability and stemness in non-small-cell lung cancer through upregulating GPX3 expression. Int J Biochem Cell Biol. 115:1055712019. View Article : Google Scholar : PubMed/NCBI
44	Worley BL, Kim YS, Mardini J, Zaman R, Leon KE, Vallur PG, Nduwumwami A, Warrick JI, Timmins PF, Kesterson JP, et al: GPx3 supports ovarian cancer progression by manipulating the extracellular redox environment. Redox Biol. 25:1010512019. View Article : Google Scholar : PubMed/NCBI
45	Sun Y, Hou L, Yang Y, Xie H, Yang Y, Li Z, Zhao H, Gao W and Su B: Two-gene signature improves the discriminatory power of IASLC/ATS/ERS classification to predict the survival of patients with early-stage lung adenocarcinoma. Onco Targets Ther. 9:4583–4591. 2016. View Article : Google Scholar : PubMed/NCBI
46	Borlado LR and Méndez J: CDC6: From DNA replication to cell cycle checkpoints and oncogenesis. Carcinogenesis. 29:237–243. 2008. View Article : Google Scholar : PubMed/NCBI